Tempest Therapeutics Inc TPST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
-
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
-
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
-
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
-
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $0.54
- Day Range
- $0.54–0.56
- 52-Week Range
- $0.50–10.93
- Bid/Ask
- $0.55 / $0.56
- Shares Outstanding
- 20.00M
- Market Cap
- $11.19M
- Volume/Avg
- 33,014 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.tempesttx.com
Valuation
|
Metric
|
TPST
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TPST
|
|---|---|
Quick Ratio | 0.18 |
Current Ratio | 0.38 |
Interest Coverage | — |
Quick Ratio
TPST
Profitability
|
Metric
|
TPST
|
|---|---|
Return on Assets (Normalized) | −111.16% |
Return on Equity (Normalized) | −389.41% |
Return on Invested Capital (Normalized) | −140.27% |
Return on Assets
TPST
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Hw@J>L? | LOCK|JBxK% | $134B | |||
| Moderna Inc
MRNA
| LOCK|MH@B>#! | LOCK|$<W | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|T$x^nP | LOCK|%#<p | $84B | |||
| argenx SE ADR
ARGX
| LOCK|>YRG#r# | LOCK|g%x | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&f?>^K% | LOCK|T! | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|qPQpn$ | LOCK|t%%r | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|dNWVY!V? | LOCK|wQZPc | $29B | |||
| Incyte Corp
INCY
| LOCK|p>%Xl? | LOCK|>W% | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|$XNPFC | LOCK|j$g | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$p%TTl% | LOCK|c@ | $14B |
United States